Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia

scientific article published on 30 January 2019

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41375-018-0364-X
P698PubMed publication ID30700841

P50authorDaniel RomoQ86809535
P2093author name stringRong Chen
William G Wierda
Shuxing Zhang
Yuling Chen
William Plunkett
Mingzhao Zhu
Kenneth G Hull
Wesley Skillern
Qun Qin
Omar Robles
Rajan R Chaudhari
P2860cites workeIF4A3 is a novel component of the exon junction complexQ24305305
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaQ24313505
Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translationQ24531417
MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2Q24563123
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridolQ24805832
Defining the role of mTOR in cancerQ28235431
Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNAQ28259974
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsQ29547463
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesisQ29547538
Molecular mechanisms of mTOR-mediated translational controlQ29615529
Natural products as sources of new drugs over the 30 years from 1981 to 2010Q29616640
Drug combination studies and their synergy quantification using the Chou-Talalay methodQ29617422
Natural products as chemical probesQ33590047
Chemo- and site-selective derivatizations of natural products enabling biological studiesQ33699233
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemiaQ33721114
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.Q33806087
Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulationQ34375074
Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine AQ34520772
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemiaQ34568840
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cellsQ35176904
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancerQ35216351
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell deathQ35848241
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaQ35958056
Isolation and identification of eukaryotic initiation factor 4A as a molecular target for the marine natural product Pateamine A.Q36965257
Diagnosing and exploiting cancer's addiction to blocks in apoptosisQ37059647
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemiaQ37187536
Natural products as probes for new drug target identificationQ37277209
Translational control in cancer.Q37717999
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cellsQ37725415
Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemiaQ37771674
Current and future directions in mammalian target of rapamycin inhibitors developmentQ37836904
Targeting the eIF4A RNA helicase as an anti-neoplastic approachQ38252428
Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agentsQ38346557
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.Q38776895
Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: negation of domain-linker regulation of activity.Q39333883
Inhibition of eukaryotic translation initiation by the marine natural product pateamine A.Q40366805
Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine.Q40801780
bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cellsQ41234110
Molecular dynamics simulation of the allosteric regulation of eIF4A protein from the open to closed state, induced by ATP and RNA substratesQ41888376
Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A.Q43559954
Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivativeQ45028817
Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay.Q48235539
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonistsQ48581580
Impact of recovery on fraction unbound using equilibrium dialysisQ48786172
The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs.Q52339079
Editorial: Strategies for cellular target identification of natural products.Q53721548
RNA-Mediated Sequestration of the RNA Helicase eIF4A by Pateamine A Inhibits Translation InitiationQ62065986
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discoveryQ82676939
Pateamine: a potent cytotoxin from the New Zealand Marine sponge, mycale sp.Q104987950
P433issue7
P921main subjectchronic lymphocytic leukemiaQ1088156
P1104number of pages12
P304page(s)1663-1674
P577publication date2019-01-30
P1433published inLeukemiaQ6534498
P1476titleCreating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia
P478volume33

Search more.